The Global Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) was valued at US$ 7,310.1 Million in 2022 and is projected to exhibit a CAGR of 5.5% during the forecast period (2022-2030).
The key market players are focusing on launching new products for the treatment of Pulmonary Arterial Hypertension, which is anticipated to boost the global pulmonary drug market. For instance, in February 2021, United Therapeutics commercially launched the Remodulin Remunity pump for the treatment of Pulmonary Arterial Hypertension. The device is small, compact, and pre-loaded with medications, providing better results than current subcutaneous pump solutions. This is expected to have a positive impact on overall market growth during the forecast period.
Global Pulmonary Arterial Hypertension Drug Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 pandemic has affected various industries globally. The players operating in the global Pulmonary Arterial Hypertension drug market are facing major challenges on various fronts due to the COVID-19 pandemic. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets.
Patients with Pulmonary Arterial Hypertension are at increased risk of COVID19. According to data from the American College of Cardiology, in August 2020, the incidence of COVID19 infection among PAH patients was 2.1 cases per 1,000 patients. This has increased the demand for PAH drugs used in treatment to control the risk of COVID19 infection. This demand has had a positive impact on the growth of the market.
Browse 35 Market Data Tables and 34 Figures spread through 174 Pages and in-depth TOC on “ Global Pulmonary Arterial Hypertension Drug Market”- Forecast to 2030, Global Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Forecast to 2030
To know the latest trends and insights prevalent in the Pulmonary Arterial Hypertension Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pulmonary-arterial-hypertension-pah-market-203
The increasing approval from regulatory authority is expected to drive the growth of global Pulmonary Arterial Hypertension drug market over the forecast period. For instance, the U.S. Food and Drug Administration (FDA) granted United Therapeutics approval for Orenitram, treprostilin tablets in October 2019. The tablets will potentially help to slow the progression of pulmonary arterial hypertension.
Key Takeaways of the Global Pulmonary Arterial Hypertension Drug Market:
- The global Pulmonary Arterial Hypertension drug market is expected to exhibit a CAGR of 5.5% during the forecast period, owing to rising cases that leads to Pulmonary Arterial Hypertension such as, pulmonary embolism, congestive heart failure, and others. For instance, according to a Heart Disease and Stroke Statistics 2019 article published by the American College of Cardiology Foundation, a report from the American Heart Association noted that in 2013 and 2016, about 6.2 million American adults suffered from heart failure (HF), and in 2014, atrial fibrillation and pulmonary embolism were the main diagnoses of approximately 454,000 and 178,000 hospitalized patients in the U.S., respectively.
- Among drug class, endothelin receptor antagonists (ERAs) segment held a dominant position in the pulmonary arterial hypertension market, owing to the increasing FDA approvals, which is expected to propel the market growth. For instance, in September 2017, the U.S. Food and Drug Administration (FDA) approved Tracleer (bosentan) for the treatment of pediatric Pulmonary Arterial Hypertension. The drug is approved for use in pediatric patients 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR).
- Major players operating in the global Pulmonary Arterial Hypertension drug market include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.
